

Domini Impact Equity FundsM

CLASS Y SHARES | DSFRX

Shareholder Report Overview

This shareholder report contains important information about the Domini Impact Equity Fund for the period of August 1, 2023 to July 31, 2024. You can find additional information about the Fund at *domini.com*. You can also request information by contacting us at 1-800-582-6757 or by emailing funddocuments@domini.com.

What were the Fund costs for last year? (based on a hypothetical \$10,000 investment)

Class Name	Cost of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Class Y shares	\$88	0.80%

How did the Fund perform last year and what affected its performance?

The Fund's Class Y Shares returned 20.51% for the trailing twelve months ended July 31, 2024, lagging the S&P 500 Index (the "benchmark"), which returned 22.15%.

Equities generally experienced strong positive returns over the period, boosted by falling inflation, resilient economic data, and expectations for lower interest rates. Mega-capitalization and growth stocks outperformed, with swelling enthusiasm around artificial intelligence (AI) driving particularly strong results for large technology stocks.

Much of the Fund's underperformance relative to the benchmark was attributable to several large benchmark holdings that do not currently meet Domini's environmental and social standards and are therefore ineligible for investment, including Meta Platforms, Eli Lilly, General Electric, and JPMorgan Chase. These impacts were partially offset by contributions from the Fund's overweight to Information Technology and lack of exposure to Energy, which the Fund does not invest in due to Domini's exclusionary standards on fossil fuels. The top individual contributor was an overweight position in technology company NVIDIA.

Top Relative Contributors ↑

Sectors:

Energy (excluded)

Information Technology (overweight)

Utilities (underweight)

Stocks:

NVIDIA Corp. (overweight)

Novo Nordisk A/S (out-of-benchmark)

Johnson & Johnson (ineligible, not held)

Top Relative Detractors ↓

Sectors:

Financials (underweight)

Communication Services (underweight)

Industrials (underweight)

Stocks:

Meta Platforms, Inc. (ineligible, not held)

Eli Lilly & Co. (ineligible, not held)

STMicroelectronics (out-of-benchmark)


Annual Shareholder Report DSFRX07312024



How has the Fund performed?

Keep in mind that the Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemption of Fund shares.

CUMULATIVE RETURNS OF A HYPOTHETICAL \$10,000 INVESTMENT (as of 7/31/2024)



Average Annual Total Returns (as of 7/31/24)

Name	1 Year	5 Years	10 Years
Class Y shares	20.51%	13.86%	10.31%
S&P 500 Index	22.15%	15.00%	13.15%

The Fund's current investment strategy commenced on December 1, 2018, with the current subadviser. Fund performance prior to that reflects the investment strategies employed at that time.

Visit domini.com/performance for the most recent performance information.

Key Fund Statistics

The following table outlines certain key Fund statistics as of the end of the reporting period:

Fund's net assets	\$1,101,493,961	
Total number of portfolio holdings	308	
Portfolio turnover rate	9%	
Total advisory fees paid	\$6,500,907	

What did the Fund invest in?


The following table identifies the Fund's top ten portfolio holdings as of the end of the reporting period:

TOP TEN HOLDINGS (% of net assets)

Apple, Inc.	7.3%
Microsoft Corp.	7.0%
NVIDIA Corp.	6.5%
Alphabet, Inc., Class A	4.2%
Amazon.com, Inc.	3.9%
Broadcom, Inc.	2.3%
Tesla, Inc.	2.0%
Novo Nordisk A/S	1.4%
Visa, Inc., Class A	1.3%
Mastercard, Inc., Class A	1.2%



SECTOR ALLOCATION (% of net assets)



Additional Information

You can find additional information on the Fund's website, domini.com/funddocuments, including its:

- Prospectus
- Fund holdings
- Financial information
- Proxy voting information

You can also request this information by contacting us at 1-800-582-6757.



Scan for more information